|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mechanism of action of the dual topoisomerase-Ⅰ and -Ⅱ inhibitor TAS-103 and activity against multidrug resistant cells 显示文摘 | Minderman H Wrzosek C Cao S | 2000 | Cancer Chemother Pharmacol2000，45，： | 1 |
| 2 | Flow cytometric analysis of breast cancer resistance protein expression and function 显示文摘 | Minderman H Suvannasankha A O'Loughlin KL | 2002 | Cytometry2002，48，： | 1 |
| 3 | Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein,multidrug resistance protein,and breast cancer resistance protein显示文摘 | Brooks TA Minderman H O' Loughlin KL | 2003 | Mol Cancer Ther2003，2，11： | 1 |
| 4 | Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function 显示文摘 | Suvannasankha A Minderman H O' Loughlin KL | 2004 | Leukemia2004，18，7： | 1 |
| 5 | Mechanism of action of the dual topoisomerase- Ⅰ and- Ⅱ inhibitor TAS-103 and activity against m μLtidrug resistant cells显示文摘 | Minderman H Wrzosk C Cao S | 2000 | Cancer Chemother Pharmacol2000，45，1： | 1 |
| 6 | Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4显示文摘 | Riddell JR Wang XY Minderman H | 2010 | J Immunol2010，184，2： | 1 |
| 7 | In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells显示文摘 | Minderman H Conroy J M O'Loughlin K L | 2005 | Mol Cancer Ther2005，4，6： | 1 |
| 8 | VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing ultidrug resistance protein, and breast cancer resistance protein显示文摘 | Minderman H O'Loughlin KL Pendyala L | 2004 | Clin Cancer Res2004，10，5： | 1 |
| 9 | Effects of doxorubicin exposure on cell-cycle kinetics of human leukemia cells studied by bivariate flow cytometric measurement of 5-iodo-2-deoxyuridine incorporation and DNA content显示文摘 | Brons PPT Linssen PCM | 1991 | Exp Hematol1991，19，： | 1 |
| 10 | Taxane- based reversal agents modulate drug resistance mediated by P- glycoprotein,multidrug resistance protein, and breast cancer resistance protein显示文摘 | Brooks T A Minderman H O' Loughlin K L | 2003 | Mol Cancer Ther2003，2，11： | 1 |
| 11 | Sequential admin- istration of irinotecan and cytarabine in the treatment of relapsed and refractery acute myeloid leukemia显示文摘 | Minderman H OLoughlin KL Smith PF | 2006 | Cancer Chemother Pharmaco12006，57，1： | 1 |
| 12 | Bortezomib activity and in vitro interactions with anthraeyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status显示文摘 | Minderman H Zhou Y O'Loughlin KL | 2007 | Cancer Chemother Pharmacol2007，60，2： | 1 |
| 13 | Dannorubicin:Preclinical and clinical pharmacorinetic studies显示文摘 | Minderman H Haanen C | 1989 | Semin Oneol1989，162，： | 1 |
| 14 | VX-710(biricodar)increasea drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein,multidrug resistance protein,and breast cancer resistance protein显示文摘 | Minderman H O'Loughlin K L Pendyala L | 2004 | Clin Cancer Res2004，10，5： | 1 |
| 15 | Rapamycin overcomes multidrug resistance(MDR) mediated by P-glycoprotein ( P-gp), multidrug resistance protein-1 ( MRP- 1), breast cancer resistance protein(BCRP)and lung resistance protein (LRP) and synergizes with substrate drugs in MDR cells显示文摘 | Pawarode A Minderman H Kieran L | 2006 | AACR Meet Abstr2006，47，4： | 1 |
| 16 | VX-710(birieodar) increase drug retention and enhances ehemosensitivity in resistant cells overexpressing P-glycoprotein,muhidrug resistance protein,and breast cancer resistance protein 显示文摘 | Minderman H O'Loughlin KL Pendyala L | 2004 | Clin Cancer Res2004，10，： | 1 |
| 17 | Idarubicin vdaunorubicin: preclinical and clinical pharmacokinetic studies显示文摘 | Speth PA Minderman H Haanen C | 1989 | Semin Oncol?1989，16，12： | 1 |
| 18 | VX-710(biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein,and breast cancer resistance protein显示文摘 | Minderman H O'Loughlin KL Pendyala L | 2004 | Clin Cancer Res2004，10，5： | 1 |
| 19 | Breast cancer resistance protein(BCRP/MXR/ABCG2)in adult acute lymphoblas-tic leukaemia:frequent expression and possible correlation with shorter disease-free survival显示文摘 | Suvannasankha A Minderman H O'loughlin KL | 2004 | Br J Haematol2004，127，11： | 1 |
| 20 | Dioc2(3) is not a substrate for muhidrug resistance protein(MRP) - mediated drug efflux显示文摘 | Minderman H Vanhoefer U Toth K | 1996 | Cytometry1996，25，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员